Accolade (NASDAQ:ACCD – Get Rating) will release its earnings data after the market closes on Thursday, April 28th. Analysts expect Accolade to post earnings of ($0.45) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.
ACCD opened at $12.91 on Thursday. Accolade has a fifty-two week low of $12.43 and a fifty-two week high of $55.47. The business has a 50-day moving average of $16.45 and a 200-day moving average of $24.42. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.21 and a quick ratio of 2.21. The company has a market capitalization of $864.43 million, a PE ratio of -7.46 and a beta of 2.02.
A number of research firms have recently weighed in on ACCD. Guggenheim assumed coverage on Accolade in a research note on Wednesday, April 6th. They set a “neutral” rating for the company. BTIG Research cut their price objective on Accolade from $60.00 to $35.00 in a research note on Tuesday, January 11th. Wells Fargo & Company assumed coverage on Accolade in a research note on Monday, April 11th. They issued an “underweight” rating and a $9.00 price objective on the stock. Morgan Stanley cut their price objective on Accolade from $31.00 to $30.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 11th. Finally, Piper Sandler cut their price objective on Accolade from $35.00 to $22.00 in a research note on Wednesday, April 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $36.92.
About Accolade (Get Rating)
Accolade, Inc develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists.
See Also
- Get a free copy of the StockNews.com research report on Accolade (ACCD)
- 3 Ways to Invest in 5G Growth
- Sell-Side Activity Drives Proctor & Gamble Higher
- Google Upgraded Ahead Of Earnings
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.